Strike While the Iron is Hot: Stryker (SYK)

Stryker (SYK) is a rarity in the current market: a strong business with a stock that is still attractively valued. A leading supplier of medical implants, surgical tools, and neurosurgical equipment in 100 countries, Stryker has grown revenue and profits every single year since 2000 and earns a top-quintile return on invested capital (ROIC). Based on Stryker’s long history of strong profit growth and key tailwinds in the medical device industry, I think the stock is undervalued at ~$84/share.

Profits Are Better Than You Think

Figure 1 shows that Stryker’s operating profit (NOPAT) rose while GAAP net income declined in 2012 and 2013. In 2013, Stryker’s NOPAT exceeded its GAAP net income by over $1 billion.

Investors should focus on NOPAT rather than net income. Last year, Stryker incurred over $1 billion in non-recurring charges related to increased liability reserves and voluntary recall costs for the company’s Rejuvenate hip replacements and Neptune waste management systems. NOPAT excludes these unusual costs.

We expect these charges to be much lower in the future as the company has already taken large reserves for the hip replacement recall and has resolved the issues with its Neptune systems. As a result, Stryker’s rising NOPAT provides a more accurate picture of the cash flows investors can expect from the company going forward.

Figure 1: Focus On NOPAT, Not Net Income

Sources: New Constructs, LLC and company filings.

Stryker increased its return on invested capital (ROIC) from 5% in 1999 to a top-quintile 30% in 2013. Even more impressively, the company has grown NOPAT every single year since 2000 at a rate of 18% compounded annually. Stryker has shown the ability to grow profits and sales in any economic climate.

Consistent cash flow growth has kept Stryker’s balance sheet in good shape. Stryker has $3.8 billion in excess cash, more than enough to cover the company’s $3 billion in total debt.

Intelligent Acquisitions Are Creating Value

We don’t usually like to see acquisition-driven growth as it tends to be a value destroyer. However, Stryker has done an excellent job of making smart acquisitions. From 2011 to 2013, management improved ROIC from 24% to 30% while completing eight acquisitions and doubling invested capital. Just as impressive, the company has kept free cash flow positive, at $1.4 billion in 2012 and $205 million in 2013. Stryker’s management has an eye for value-creating acquisitions.
Here are a few of the smaller competitors the company gobbled up recently: Small Bone Innovations on Aug. 1, 2014 for $375 million; Patient Safety Technologies (PSTX) in Dec. 2013 for $120 million; MAKO Surgical Group (MAKO) in Dec. 2013 for $1.65 billion; and Trauson Holdings Company in March 2013 for $764 million.

Organic sales growth has been good too. Revenue growth, excluding growth from acquisitions, was 4.8% in the most recent quarter and Stryker expects it to be in the range of 4.5-6.0% for 2014.

**David Beats Goliaths**

Stryker is not the largest player in the medical device industry — but it is the most competitive. Its closest competitors are Zimmer Holdings (ZMH), Medtronic (MDT), giant Johnson & Johnson’s DePuy division (JNJ), and Abbott Laboratories (ABT). With the exception of Zimmer, all of these competitors are significantly larger than Stryker.

Figure 2 shows that Stryker has the highest ROIC of its competitors, the highest operating profit margins, the highest **capital efficiency**, and the best revenue growth since 2009.

**Figure 2: Stryker Outperforms The Competition**

<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>ROIC</th>
<th>NOPAT Margin</th>
<th>Invested Capital Turns</th>
<th>Revenue CAGR Since 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stryker</td>
<td>SYK</td>
<td>30%</td>
<td>24%</td>
<td>1.24</td>
<td>8%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>JNJ</td>
<td>15%</td>
<td>21%</td>
<td>0.71</td>
<td>4%</td>
</tr>
<tr>
<td>Zimmer Holdings</td>
<td>ZMH</td>
<td>16%</td>
<td>24%</td>
<td>0.67</td>
<td>3%</td>
</tr>
<tr>
<td>Medtronic</td>
<td>MDT</td>
<td>14%</td>
<td>24%</td>
<td>0.55</td>
<td>3%</td>
</tr>
<tr>
<td>Abbot Laboratories</td>
<td>ABT</td>
<td>6%</td>
<td>12%</td>
<td>0.52</td>
<td>-8%</td>
</tr>
</tbody>
</table>

Sources: New Constructs, LLC and company filings.

There are only a few things that could slow Stryker’s excellent profit growth: the recent 2.3% medical device excise tax, and risks of future device recalls. The first issue affects the entire industry and does not affect relative competitiveness. The second is not large enough to damage the case for this stock. Even if we include the cost of recalls, net income has grown by over 12% compounded annually since 2000, which is still well above current market expectations as detailed below.

**Cheap Valuation, Limited Downside and Near-Term Catalyst**

Despite Stryker’s consistent and excellent track record of profitability, the company’s stock price implies little future growth. SYK’s current price of ~$84/share gives the stock a price-to-economic book value (PEBV) of just 1.1. This ratio implies that Stryker will grow NOPAT from its current level by only 10% for the remainder of the company’s life. This expectation seems very pessimistic considering that the company has grown NOPAT by 18% compounded annually for the past 13 years.

Investors are overly concerned with Stryker’s recall costs. So, let’s take a look at how they could affect valuation: assume another $500 million hit to cash flow next year to deal with the ongoing hip recalls. After that, if SYK can grow NOPAT by 8% compounded annually for 13 years, **the stock is worth $120/share** — 50% upside from current levels.

If the company can grow NOPAT by 12% compounded annually for 11 years (still assuming the $500 million hit to cash flow next year), **the stock has a fair value of ~$164/share** — 100% upside.

Downside in the stock is mitigated not only by the cheap valuation but also the company’s share repurchase program. Stryker repurchased 4.8 million shares in 2013, and the company still has $600 million authorized for additional buybacks into next year. Stryker’s buybacks of over $1 billion since 2011 result in an annual buyback yield of 1.1%.

Before the end of this year, we expect the company to deliver a positive earnings surprise. Given that after-tax cash flows have recently outpaced net income (as seen in Figure 1), the company is positioned to beat analysts’ estimates.
Longer term, we see three key tailwinds that will sustain Stryker’s strong profit growth.

1. Health trends — An aging and overweight U.S. population creates higher demand for medical devices, especially joint replacements. Advances in joint replacement technology have also delivered longer-lasting joint replacements, which enable doctors to suggest these implants earlier in life.

2. Health reform — Increased insurance coverage under the Affordable Care Act will make expensive joint replacements and medical care accessible to a larger segment of the population.

3. International growth — International markets only account for 34% of Stryker’s sales. There is additional room for growth here as Stryker develops sales relationships with physicians outside of the United States. Stryker’s purchase of China’s Trauson Holdings in 2013 has given the company an important foothold to establish its brand in Asia.

Ignore the Price to Earnings Ratio

SYK’s current price to earnings ratio of 44 is too high for many investors, but this ratio overstates the stock’s valuation because of understated accounting earnings as detailed at the beginning of this report.

I recently wrote an entire report on why P/E ratios are flawed as a valuation metric. Investors need to focus on cash flows and more comprehensive metrics to find value in this market.

Insiders Holding Onto Their Shares

In the past 3 months, insiders have sold 537,625 shares, which accounts for less than 1% of insider-held shares. Insiders are hanging on to their shares and investors should follow their lead.

*André Rouillard contributed to this report.*

Disclosure: David Trainer owns SYK. David Trainer and André Rouillard receive no compensation to write about any specific stock, sector or theme.
How New Constructs Creates Value for Clients

1. **Superior Recommendations** – Our stock picks consistently outperform. See our track record in our stock-picking accolades and Proof Is In Performance reports.

2. **More Accurate Research** – Our patented Research Platform for reversing accounting distortions and discounted cash flow analysis leverages better data to deliver smarter research.

3. **Time Savings** – We check the fine print in thousands of corporate filings so you don't have to. As reported by Barron's, our expertise in analyzing SEC filings delivers Hidden Gems and Red Flags that drive long-term stock-picking success.

4. **Transparency** – We are proud to share the results of our analysis of over 50,000 10Ks. Request the Corporate Disclosure Transgressions report we provided the SEC. Our reports detail all data and assumptions. Company Models enable users to change them.

5. **Objectivity** – New Constructs is an independent research firm, not tied to Wall Street or investment banking services. Our models are driven by comprehensive high-quality data not stories. See our presentation to the Senate Banking Committee, the SEC and many others in DC.

Our Philosophy About Research

Accounting data is not designed for equity investors, but for debt investors. Accounting data must be translated into economic earnings to understand the profitability and valuation relevant to equity investors. Respected investors (e.g. Adam Smith, Warren Buffett and Ben Graham) have repeatedly emphasized that accounting results should not be used to value stocks. Economic earnings are what matter because they are:

1. Based on the complete set of financial information available.
2. Standard for all companies.
3. A more accurate representation of the true underlying cash flows of the business.

Additional Information

Incorporated in July 2002, New Constructs is an independent publisher of investment research that provides clients with consulting, advisory and research services. We specialize in quality-of-earnings, forensic accounting and discounted cash flow valuation analyses for all U.S. public companies. We translate accounting data from 10Ks into economic financial statements, i.e. NOPAT, Invested Capital, and WACC, to create economic earnings models, which are necessary to understand the true profitability and valuation of companies. Visit the Free Archive to download samples of our research. New Constructs is a BBB accredited business and a member of the Investorside Research Association.
DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, “New Constructs”) is an independent organization with no management ties to the companies it covers. None of the members of New Constructs’ management team or the management team of any New Constructs’ affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs’ Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

New Constructs is affiliated with Novo Capital Management, LLC, the general partner of a hedge fund. At any particular time, New Constructs’ research recommendations may not coincide with the hedge fund’s holdings. However, in no event will the hedge fund receive any research information or recommendations in advance of the information that New Constructs provides to its other clients.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs’ reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs.

Copyright New Constructs, LLC 2003 through the present date. All rights reserved.